Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-10-05T16:33:28Z
Fecha de publicación2015-01-01
ResumenTumor cells frequently metastasize to bone where they can generate cancer-induced bone pain (CIBP) that can be difficult to fully control using available therapies. Here, we explored whether PLX3397, a high-affinity small molecular antagonist that binds to and inhibits phosphorylation of colony-stimulating factor-1 receptor, the tyrosine-protein kinase c-Kit, and the FMS-like tyrosine kinase 3, can reduce CIBP. These 3 targets all regulate the proliferation and function of a subset of the myeloid cells including macrophages, osteoclasts, and mast cells. Preliminary experiments show that PLX3397 attenuated inflammatory pain after formalin injection into the hind paw of the rat. As there is an inflammatory component in CIBP, involving macrophages and osteoclasts, the effect of PLX3397 was explored in a prostate model of CIBP where skeletal pain, cancer cell proliferation, tumor metastasis, and bone remodeling could be monitored in the same animal. Administration of PLX3397 was initiated on day 14 after prostate cancer cell injection when the tumor was well established, and tumor-induced bone remodeling was first evident. Over the next 6 weeks, sustained administration of PLX3397 attenuated CIBP behaviors by approximately 50\% and was equally efficacious in reducing tumor cell growth, formation of new tumor colonies in bone, and pathological tumor-induced bone remodeling. Developing a better understanding of potential effects that analgesic therapies have on the tumor itself may allow the development of therapies that not only better control the pain but also positively impact disease progression and overall survival in patients with bone cancer.es_ES
Doihttps://doi.org/10.1097/j.pain.0000000000000228es_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/5296
Idiomaenes_ES
EditorialLIPPINCOTT WILLIAMS \& WILKINSes_ES
RelaciónPaines_ES
URL relacionadohttps://doi.org/10.1097/j.pain.0000000000000228es_ES
DerechosAcceso abierto (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_abf2es_ES
FuentePain
Palabra claveMacrophagees_ES
Palabra claveMast celles_ES
Palabra claveOsteoblastes_ES
Palabra claveOsteoclastes_ES
Palabra claveDisease progressiones_ES
Palabra claveSurvivales_ES
Palabra clavePaines_ES
TítuloTargeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone canceres_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorThompson, Michelle L.
AutorJimenez-Andrade, Juan M.
AutorChartier, Stephane
AutorTsai, James
AutorBurton, Elizabeth A.
AutorHabets, Gaston
AutorLin, Paul S.
AutorWest, Brian L.
AutorMantyh, Patrick W.
AutorThompson, Michelle L.es_ES
AutorJimenez-Andrade, Juan M.es_ES
AutorChartier, Stephanees_ES
AutorTsai, Jameses_ES
AutorBurton, Elizabeth A.es_ES
AutorHabets, Gastones_ES
AutorLin, Paul S.es_ES
AutorWest, Brian L.es_ES
AutorMantyh, Patrick W.es_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
Número9es_ES
Rango de páginas1692-1702es_ES
URL relacionadahttps://doi.org/10.1097/j.pain.0000000000000228
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen156es_ES

Files

Collections

Documentación Cientifica